Stock of the Day

April 25, 2024

Solana (HSDT)

$2.35
+$0.13 (+5.9%)
Market Cap: $134.83M

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

Today's Trend

Solana Company (NASDAQ: HSDT) is under pressure as investors weigh a disappointing quarterly report against progress in its Solana staking and validator businesses.

  • Solana Company expects to receive its first validator-related rewards in the third quarter of 2026 after committing 500,000 SOL to support its Tokyo validator cluster. The initiative could create an additional recurring revenue stream and expand the company’s institutional presence in Asia-Pacific. Solana Company expects first validator-related rewards
  • Second-quarter revenue rose to approximately $2.5 million from $43,000 a year earlier, primarily from staking. The company also earned 31,200 SOL in staking rewards, completed the divestiture of its legacy PoNS medical-device business, launched its first Tokyo institutional validator cluster and raised $7.9 million through a registered direct offering. Solana Company Reports Second Quarter 2026 Financial Results
  • The earnings call highlighted the company’s strategy of combining SOL treasury management, staking, validator infrastructure and advisory services. Execution of these initiatives may increase long-term value, but future rewards and business growth remain dependent on SOL prices, capital availability and adoption. Solana Company Q2 2026 Earnings Call Transcript
  • Quarterly results missed expectations: adjusted loss was $0.05 per share versus the expected $0.02 loss, while revenue of $2.53 million fell short of the $3.50 million consensus estimate. Solana Company Reports Q2 Loss, Lags Revenue Estimates
  • GAAP net loss expanded to $30.3 million, with operating expenses reaching $35.1 million, including elevated administrative and divestiture costs. The company had only $3.6 million in cash at quarter-end and an accumulated deficit of $342.6 million, increasing concerns about profitability and financing needs.
  • Wall Street Zen downgraded HSDT to “Sell,” adding to the negative reaction to the earnings miss and continued losses. Wall Street Zen Downgrades Solana to Sell
← Previous Stock of the DayNext Stock of the Day →

Recent News